News

Diabetes insulin pens by Novo Nordisk to be phased out: How will it impact dosage and treatment?
Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...
NBC Los Angeles4d
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Will Indians get blockbuster weight-loss drugs at cost of cheaper insulin?
Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...
Novo: On Track To The Mid $40s While Losing Market Share To Eli Lilly
Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...
Novo Nordisk clarifies Mixtard insulin vials will still be available, as penfills get phased out
Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Novo Nordisk to phase out country’s largest insulin brand
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...
24/7 Wall St.8d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...